The rejection of Disc Medicines experimental compound for a rare and devastating disorder by the FDA is the latest example of the growing uncertainty at the nation’s top drug regulator https://www.bloomberg.com/news/articles/2026-02-13/rare-malady-drug-goes-from-fda-priority-to-reject-in-four-months?taid=698fb005c242da000139f441&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter